ROCKVILLE, Md., Dec. 17, 2015 (GLOBE NEWSWIRE) -- The United States Pharmacopeial Convention (USP) announced that Salah D. Kivlighn, Ph.D., has assumed the role of Senior Vice President, Strategic Marketing and Program Operations (SMPO). Dr. Kivlighn reports to USP's Chief Executive Officer, Ronald T. Piervincenzi, and is a member of the organization's executive team.
A new division in the organizational structure, Strategic Marketing and Program Operations will work in direct partnership with USP's Science Division responsible for the technical and scientific development of USP's quality standards. SMPO will focus on understanding customer needs and specifications, monitoring marketing efficiency and effectiveness and further developing USP's brand strategy.
"Being able to better understand the unmet and emerging needs of our key stakeholders will enable USP to strengthen its quality-related programs in chemical medicines, biologics, excipients, dietary supplements, food ingredients and healthcare practice," said Dr. Kivlighn. The SMPO unit for each of these areas will report to Dr. Kivlighn
Most recently, Dr. Kivlighn was Vice President of Marketing at Kite Pharma, a company focused on cell-based immuno-oncology. For eight years, Kivlighn held global leadership positions in product development and marketing at MedImmune, where he was responsible for regulatory filings; clinical and commercial development and chemistry, manufacturing and controls (CMC) related to numerous oncology and autoimmunity products. Dr. Kivlighn also led marketing teams and initiatives at NABI Biopharmaceuticals and Merck & Co., Inc. related to pipelines, launches and planning for vaccine and cardiovascular products.
Dr. Kivlighn received a B.S. in Distributed Studies from Iowa State University and a Ph.D. in Pharmacology from the University of Houston. Dr. Kivlighn also completed a fellowship in integrated physiology in the Department of Physiology at the University of Mississippi Medical School. He has authored more than 70 peer-reviewed publications and has completed a variety of executive training programs at the Wharton School of Business.
"Being able to leverage the kind of expertise and experience Salah brings with him to USP will help optimize the public health impact of each of our program units," said Dr. Piervincenzi. "We're pleased to have Salah as part of the USP leadership team."
For additional information, contact [email protected].
USP – Global Expertise, Trusted Standards, Improved Health
The U.S. Pharmacopeial Convention (USP) is a global health organization that improves lives through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. USP's standards are used worldwide. For more information about USP, visit http://www.usp.org.
CONTACT: Theresa Laranang-Mutlu
301-816-8167
[email protected]


FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



